Abstracts tagged "Adult-onset Still’s disease"

Abstract Number: 784 • 2019 ACR/ARP Annual Meeting
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Cristina Segu-Verges¹, Mireia Coma ¹, Christoph Kessel ², Serge Smeets ³, Dirk Foell ² and Anna Aldea ⁴, ¹Anaxomics, Barcelona, Catalonia, Spain, ²University Hospital Muenster, Muenster, Germany, ³Novartis, Amsterdam, Netherlands, ⁴Novartis, Barcelona, Catalonia, Spain
Background/Purpose: Systemic JIA (sJIA) and Adult Onset Still’s Disease may represent a disease continuum1 of the same autoinflammatory disorder, Still’s Disease. Current challenges in its…
Abstract Number: 1245 • 2019 ACR/ARP Annual Meeting
Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease
Corrado Campochiaro¹, Alessandro Tomelleri ², De Luca Giacomo ³, Nicola Farina ², Elena Baldissera ², Giulio Cavalli ² and Lorenzo Dagna ², ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory condition characterized by fever, arthritis, skin rash, and multi-organ inflammation. The pathogenesis of AOSD is centrally…
Abstract Number: 1250 • 2019 ACR/ARP Annual Meeting
Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?
Emre Bilgin ¹, Timuçin Kaşifoğlu ², Ahmet Omma ³, Cemal Bes ⁴, Muhammet Çınar ⁵, Hakan Emmungil ⁶, Orhan Küçükşahin ⁷, Servet Akar ⁸, Kenan Aksu ⁹, Fatih Yıldız ¹⁰, Nilüfer Kanıtez ¹¹, Abdulsamet Erden ¹², Sezin Turan ¹³, Ediz Dalkılıç ¹⁴, Selime Ermurat ¹⁵, Mutlu Hayran ¹⁶ and Umut Kalyoncu¹⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, ³Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴University of Medical Sciences, İstanbul, Turkey, ⁵University of Medical Sciences, Ankara, Turkey, ⁶Trakya University, Edirne, Turkey, ⁷Liv Hospital, Ankara, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁰Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaraş, Turkey, ¹¹Koç University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ¹²Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹³Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey, ¹⁴Uludağ University, Bursa, Turkey, ¹⁵Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, ¹⁶Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, ¹⁷Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare, chronic and auto-inflammatory disorder with multisystemic involvement. Patient Acceptable Symptom State (PASS) is the highest level of…
Abstract Number: 1262 • 2019 ACR/ARP Annual Meeting
Clinical Features of Elderly-onset Adult Still’s Disease
Sayaka Takenaka¹, Takehisa Ogura ¹, Yuto Takakura ¹, Takaharu Katagiri ¹, Yuki Inoue ¹, Ayako Hirata ¹ and Hideto Kameda ², ¹Division of Rheumatology, Department of Internal medicine Toho University Ohashi Medical Center, Tokyo, Japan, ²Toho University, Tokyo, Japan, Tokyo, Japan
Background/Purpose: The peak age at the onset of adult Still's disease (ASD) has been between 20 and 35 years old. However, the proportion of elderly-onset…
Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting
Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Martin Michaud¹, Thomas Sene ², Pascal Chazerain ², Geoffrey Urbanski ³, Frederique Retornaz ⁴, Boris Bienvenu ⁵, Laurent Chiche ⁴, Florian Catros ⁶, Laurent Sailler ⁷, Laurent Alric ⁸, Jean Thomas Giraud ⁹, Léo Caudrelier ¹⁰, Slim Lassoued ¹⁰, Sophie Ancellin ⁶, Olivier Lidove ² and Francis Gaches ⁶, ¹Joseph Ducuing Hospital, Toulouse, France, ²Hôpital Croix Saint Simon, Paris, France, ³CHU Angers, Angers, France, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Saint Joseph, Marseille, France, ⁶Hôpital Joseph Ducuing, Toulouse, France, ⁷University Hospital of Toulouse, Toulouse, France, ⁸CHU Toulouse, Toulouse, France, ⁹Hôpital de Tarbes, Tarbes, France, ¹⁰Hôpital de Cahors, Cahors, France
Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
Abstract Number: 1271 • 2019 ACR/ARP Annual Meeting
Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment
Ivette Casafont-Solé¹, Susana Holgado ¹, Javier Narváez ², Maribel Mora ³, Josep Roca ⁴, Anahy Brandy-Garcia ¹, Lourdes Mateo ¹, Melania Martínez-Morillo ¹, Laia Gifre ¹, Maria Aparicio-Espinar ¹, Águeda Prior-Español ¹, Anne Riveros-Frutos ¹, Clara Sangüesa ¹, Jordi Camins-Fàbregas ¹, Annika Nack ¹, Joan Miquel Nolla ³ and Alejandro Olivé-Marqués ⁴, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
Background/Purpose: Adult-onset Still’s disease (AOSD) is a low prevalent disease with an unpredictable clinical course and variable prognosis. Sometimes, it requires biologic treatment in early…
Abstract Number: 32 • 2019 ACR/ARP Annual Meeting
Aberration of Histone Lysine Methylation in Adult-Onset Still’s Disease Are Novel Biomarker Candidates Associated with the Disease Activity
Yoshimi Aizaki¹, Yasuto Araki ¹, Kojiro Sato ² and Toshihide Mimura ¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan
Background/Purpose: Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by spiking fever, transient rash, arthritis and leukocytosis. Macrophage and neutrophil activation is a…
Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting
The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study
Haiting Wang¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye², ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
Abstract Number: 1154 • 2017 ACR/ARHP Annual Meeting
Use of Including Serum Ferritin and Heme Oxygenase 1 in the Yamaguchi’s Classification for Adult-Onset Still’s Disease: A Multicenter Retrospective Study
Yohei Kirino¹, Yasushi Kawaguchi², Yoshifumi Tada³, Hiroshi Tsukamoto⁴, Toshiyuki Ota⁵, Masahiro Iwamoto⁶, Hiroki Takahashi⁷, Kohei Nagasawa⁸, Syuji Takei⁹, Takahiko Horiuchi¹⁰, Hisae Ichida², Seiji Minota¹¹, Atsuhisa Ueda¹, Akihide Ohta¹² and Yoshiaki Ishigatsubo¹³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ⁴Department of medicine and biosystemic science, Kyushu University Hospital, Fukuoka, Japan, ⁵Department of Rheumatology, Iizuka Hospital, Iizuka, Japan, ⁶Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸Rheumatic Disease Center, Sawara Hospital, Sawara, Japan, ⁹Pediatrics of Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ¹⁰Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ¹¹Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ¹²Saga University School of Medicine, Saga, Japan, ¹³Yokohama City University, Yokohama, Japan
Background/Purpose: Yamaguchi’s criteria for classification of adult-onset Still’s disease (AOSD) has been widely applied in clinic despite it was established decades ago. However, hyperferritinemia, which…
Abstract Number: 1164 • 2017 ACR/ARHP Annual Meeting
Spectrum of Skin Eruption and Histological Findings in Adult-Onset Still’s Disease and Significance of Atypical Persistent Skin Eruptions
Elina Zuelgaray¹, Maxime Battistella², Camille Sallé de Chou¹, Patrice Cacoub³, François Chasset⁴, Christopher Rein⁵, Nathan Peiffer-Smadja³, Fanny Domont³, Marie Chapalain⁶, Claude Bachmeyer⁴, Laurence Fardet⁶, Bruno Fautrel⁷, Martine Bagot¹ and Jean-David Bouaziz¹, ¹Dermatology Department, Saint-Louis Hospital, Paris, France, ²Pathology Department, Saint-Louis Hospital, Paris, France, ³Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁴Dermatology Department, Tenon Hospital, Paris, France, ⁵Rheumatology Department, Hautepierre Hospital, Paris, France, ⁶Dermatology Department, Mondor Hospital, Paris, France, ⁷UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: Adult-onset Still disease (AOSD) is a rare systemic inflammatory disorder characterized by spiking fevers, polyarthritis and an evanescent salmon-pink maculopapular eruption. Several cases of…
Abstract Number: 252 • 2016 ACR/ARHP Annual Meeting
Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
Seung Taek Song¹, SuMan Kang², Sung Won Lee³, Seoung Wan Nam², Hyukhee Kwon² and Dae-Hyun Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cheongju St. Mary's Hospital, Cheongju, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Several studies have reported that pro-inflammatory cytokines including interleukin (IL)-1, IL-6,…
Abstract Number: 263 • 2015 ACR/ARHP Annual Meeting
Use of Serum Ferritin and Heme Oxygenase 1 for the Diagnosis of Adult-Onset Still’s Disease: A Preliminary Report of Multicenter Study
Yohei Kirino¹, Yasushi Kawaguchi², Yoshifumi Tada³, Seiji Minota⁴, Toshiyuki Ota⁵, Kohei Nagasawa⁶, Hiroshi Tsukamoto⁷, Syuji Takei^8,9, Takahiko Horiuchi¹⁰, Hiroki Takahashi¹¹, Hisae Ichida², Masahiro Iwamoto⁴, Atsuhisa Ueda¹, Akihide Ohta¹², Yoshiaki Ishigatsubo^1,13 and Hypercytokinemia Study Group, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ⁴Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁵Department of Rheumatology, Iizuka Hospital, Iizuka, Japan, ⁶Rheumatic Disease Center, Sawara Hospital, Fukuoka, Japan, ⁷First Dept of Internal Med, Kyushu University, Fukuoka, Japan, ⁸School of Health Sciences, Faculty of Medicine,, Kagoshima University, Kagoshima City, Japan, ⁹School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ¹⁰Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ¹¹epartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ¹²Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan, ¹³Yokosuka Rheumatic Diseases Center, Yokosuka City Hospital, Yokosuka, Japan
Background/Purpose: Yamaguchi's criteria for classification of adult-onset Still's disease (AOSD) has been widely applied in clinic despite it was established decades ago. However, hyperferritinemia, which…
Abstract Number: 268 • 2015 ACR/ARHP Annual Meeting
TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations
Hyoun-Ah Kim¹, In Je Kim², Jae Ho Han³, Juyang Jung⁴, Chang-Hee Suh⁴ and You-Sun Kim⁵, ¹Department of Rheumatology, Ajou University School of Medicine, Suwan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ³Department of Pathology, Ajou University School of Medicine, Suwon, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁵Department of Biochemistry and Molecular biology, Ajou University School of Medicine, Suwon, South Korea
Background/Purpose: S100A8 and S100A9 are two calcium-binding proteins that belong to the S100 family, and those are expressed by infiltrating monocytes and neutrophils under inflammatory…
Abstract Number: 1400 • 2015 ACR/ARHP Annual Meeting
Hyperferritinemia and Fever in Adults
Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan
Background/Purpose: Clinical associations of hyperferritinemia include: hepatocellular injury, hemophagocytic lymphohistiocytosis (HLH), hematologic malignancy, adult-onset Still’s disease (AOSD), and iron overload. Fever of undetermined origin (FUO)…
Abstract Number: 1243 • 2014 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Complicating Adult Onset Still’s Disease – Single Center Experience and Literature Review
Aleksander Lenert¹ and Qingping Yao², ¹Orthopaedic and Rheumatologic Institute, Dept. of Rheumatic & Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening complication typically associated with hematologic malignancies and infections. HLH, also referred to as macrophage activation syndrome (MAS),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].